Stock AnalizIntegra Lifesciences Holdings Corp. IART
Medical/Dental Instruments · data as of November 13, 2026
Integra Lifesciences Holdings Corp. (IART) is a healthcare company listed in the US with a market value of about $1.1B. In the twelve months to September 30, 2026 it had revenue of $1.7B and net income of $13M, a net margin of 0.8%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is shareholder returns (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 84.7, a price to free cash flow of 13.1, 5-year revenue growth of 4% a year, a 5-year average ROIC of 0%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 24% below the current price.
Score: 1.0 / 5
Checks passed
- P/FCF below 20
- Strong R&D investment or growth above 20%
- Positive free cash flow
- Share count down over 3 years (buybacks)
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.6B | $1.6B | $1.5B | $1.6B | $1.5B | $1.4B | $1.5B | $1.5B | $1.2B | $992M |
| Net income | $13M | -$516M | -$7M | $68M | $181M | $169M | $134M | $50M | $61M | $65M | $75M |
| Free cash flow | $86M | -$31M | $25M | $73M | $222M | $264M | $165M | $162M | $122M | $71M | $69M |
| EPS (diluted) | $0.17 | $-6.74 | $-0.09 | $0.84 | $2.16 | $1.98 | $1.57 | $0.58 | $0.72 | $0.82 | $0.94 |
| Net margin | 0.8% | -31.6% | -0.4% | 4.4% | 11.6% | 11.0% | 9.8% | 3.3% | 4.1% | 5.5% | 7.5% |
| ROIC | — | -15.3% | 0.9% | 3.7% | 7.3% | 5.9% | 4.8% | 3.3% | 3.4% | 1.3% | 11.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $15.67, 9% above the current price; targets range from $13.00 to $23.00; the consensus rating is “Hold”; expected EPS is $2.34 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Integra Lifesciences Holdings’s P/E ratio?
About 84.7, based on the last twelve months of diluted earnings per share (forward P/E about 6.2).
Is Integra Lifesciences Holdings stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 24% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Integra Lifesciences Holdings pay a dividend?
Not currently.
Is Integra Lifesciences Holdings a good stock to buy?
We do not give buy or sell advice. Integra Lifesciences Holdings scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.